Overview

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

Status:
Terminated

Trial end date:
2018-01-29

Target enrollment:

Participant gender:

Summary

A Phase 2b study to evaluate the efficacy and safety of brazikumab (MEDI2070) in participants with moderate to severe Crohn's disease who have failed or are intolerant to anti-tumor necrosis factor-alpha (anti-TNFα) therapy.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca
MedImmune LLC

Collaborator:

AstraZeneca

Treatments:

Antibodies, Monoclonal